U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H22NOS2.Cl
Molecular Weight 355.946
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIMEPIDIUM CHLORIDE

SMILES

[Cl-].COC1CC(C[N+](C)(C)C1)=C(C2=CC=CS2)C3=CC=CS3

InChI

InChIKey=QKMGSNFPZNTQHE-UHFFFAOYSA-M
InChI=1S/C17H22NOS2.ClH/c1-18(2)11-13(10-14(12-18)19-3)17(15-6-4-8-20-15)16-7-5-9-21-16;/h4-9,14H,10-12H2,1-3H3;1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula C17H22NOS2
Molecular Weight 320.493
Charge 1
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Timepidium bromide is a quaternary ammonium antimuscarinic used for the symptomatic treatment of visceral spasms. It is a muscarinic antagonist.

CNS Activity

Curator's Comment: Timepidium does not cross the blood–brain barrier

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Sesden

Approved Use

Visceral spasms
Doses

Doses

DosePopulationAdverse events​
15 mg single, intravenous
Highest studied dose
Dose: 15 mg
Route: intravenous
Route: single
Dose: 15 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
30 mg 3 times / day multiple, oral
Recommended
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Disc. AE: Eosinophilic pustular folliculitis...
AEs leading to
discontinuation/dose reduction:
Eosinophilic pustular folliculitis
Sources:
AEs

AEs

AESignificanceDosePopulation
Eosinophilic pustular folliculitis Disc. AE
30 mg 3 times / day multiple, oral
Recommended
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010-12
Multiple granulomatous inflammation in the minor salivary glands: a proposed new entity, allergic granulomatous sialadenitis.
2004-11
Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide.
2002
Patents

Sample Use Guides

Adult Dosage: 30mg x 3 times a day.
Route of Administration: Oral
In Vitro Use Guide
Timepidium inhibited dose-dependently the contraction of isolated guinea pig gallbladder evoked by stimulation at 5 Hz. The mean dose producing a 50 % decrease in the electrically induced contraction (ID50 value) was 2.4 x 10(-8) g/ml. Timepidium (10(-6) g/ml) also inhibited, for the most part, the contraction induced by stimulation at 30 Hz.
Substance Class Chemical
Created
by admin
on Tue Apr 01 16:54:35 GMT 2025
Edited
by admin
on Tue Apr 01 16:54:35 GMT 2025
Record UNII
W5689X6OZE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIPERIDINIUM, 3-(DI-2-THIENYLMETHYLENE)-5-METHOXY-1,1-DIMETHYL-, CHLORIDE
Preferred Name English
TIMEPIDIUM CHLORIDE
Common Name English
PIPERIDINIUM, 3-(DI-2-THIENYLMETHYLENE)-5-METHOXY-1,1-DIMETHYL-, CHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
13604123
Created by admin on Tue Apr 01 16:54:35 GMT 2025 , Edited by admin on Tue Apr 01 16:54:35 GMT 2025
PRIMARY
FDA UNII
W5689X6OZE
Created by admin on Tue Apr 01 16:54:35 GMT 2025 , Edited by admin on Tue Apr 01 16:54:35 GMT 2025
PRIMARY
CAS
100595-66-2
Created by admin on Tue Apr 01 16:54:35 GMT 2025 , Edited by admin on Tue Apr 01 16:54:35 GMT 2025
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY